# US 2022/0033407 A1 · N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033407 A1
- Document ID: US20220033407A1
- Status: Published application
- Kind: A1
- Application number: 17/414,672
- Filed: 2019-12-13
- Published: 2022-02-03
- Earliest claimed: 2018-12-18
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Mihai D. Azimioara; Bei Chen; Robert Epple; Declan Hardy; Ayako Honda; Philip Lam; Hasnain Ahmed Malik; Fabio Meier; Truc Ngoc Nguyen; Barun Okram; Sejal Patel; Rodrigo Rodriguez; Duncan Shaw; Yiping Shen; Baogen WU
- Web page: https://patentgrep.com/patent/US20220033407A1

## CPC

- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 487/10: Spiro-condensed systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 471/10: Spiro-condensed systems
- C07D 491/107: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt thereof:
wherein:
ring A is pyridinyl or phenyl;
ring B is pyridinyl or phenyl;
R1 and R2 combine to form a C3-6 cycloalkyl wherein said C3-6 cycloalkyl is optionally substituted with 1, 2 or 3 halogens;
R3 is —O—R3′, —NH—R3′, phenyl, pyridyl, C9-10 heteroaryl, C3-8 cycloalkyl, C4-7 heterocycloalkyl, C6-12 spirocycloalkyl, spirocyclic heterocycle, a 7 to 10 membered fused heterocycle, C5-6 heterocycloalkene or C3-6 cycloalkene, wherein said phenyl, pyridyl, C9-10 heteroaryl, C3-8 cycloalkyl, C4-7 heterocycloalkyl, C6-12 spirocycloalkyl, spirocyclic heterocycle, C5-6 heterocycloalkene or C3-6 cycloalkene is optionally substituted with 1 to 4 substituents each independently selected from halogen, CD3, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, pyridinyl and halo-substituted-C1-4alkoxy, or R3 is C1-4alkyl, CD3, C1-5alkoxy or C1-4alkenyl, wherein said C1-4alkyl, C1-4alkenyl or C1-4alkoxy is optionally substituted with 1 to 3 substituents each independently selected from halogen and an optionally substituted phenyl wherein said phenyl is substituted with halo-substituted-C1-2alkyl, methyl or 1, 2 or 3 halogens;
R3′ is —C0-3alkyl-C3-8 cycloalkyl, or a fully or partially saturated —C9-10bicycloalkyl, wherein said —C0-3alkyl-C3-8 cycloalkyl or fully or partially saturated —C9-10bicycloalkyl is optionally substituted with C1-4alkyl;
R4 is C1-4alkyl, C1-4alkoxy, CD3, halogen or halo-substituted-C1-4alkyl;
R5 is —NR7R8 or R9;
R6 is hydrogen or halogen;
R7 is hydrogen, C1-6alkyl, C3-6 cycloalkyl, C4-7 heterocycloalkyl, wherein said C1-6alkyl, C3-6 cycloalkyl or C4-7 heterocycloalkyl is optionally substituted with 1 to 4 substituents each independently selected from deuterium, hydroxy, C1-4alkoxy, C1-4alkyl and C3-6 cycloalkyl;
R8 is hydrogen or C1-4alkyl;
R9 is a saturated C4-7 heterocycloalkyl optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, optionally substituted phenyl, optionally substituted pyridinyl, NHR11, —C(O)—R13, —C(O)NHR12, C1-4alkyl-C(O)OR12 and —C(O)O—R12, wherein said optionally substituted phenyl or pyridinyl, is substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino and C1-4alkyl, or R9 is perdeuterated morpholinyl, a 7 to 10 membered fused heterocycle or spirocyclic heterocycle optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, C3-6 cycloalkyl, phenyl, C4-6 heterocycle, NHR1, —S(O)2—R15, —C(O)—R13, —C(O)NHR11, C1-4alkyl-C(O)OR12, —C(O)C1-3alkyl-NHR11 and —C(O)O—R12, wherein said phenyl, C3-6 cycloalkyl and C4-6 heterocycle are optionally substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino, C1-4alkyl, halo-substituted-C1-4alkyl and hydroxy-substituted-C1-4alkyl;
R11 is hydrogen, C1-4alkyl, —C(S)NH—R15, —C(O)NH—R15, —C(O)R15 or C0-3alkyl-C(O)O—R14;
R12 is hydrogen, C1-4alkyl, C3-6 cycloalkyl or C1-3alkyl-C(O)—NHR14;
R13 is C1-4alkyl, wherein said alkyl is optionally substituted with amino;
R14 is hydrogen or C1-4alkyl; and
R15 is C3-6 cycloalkyl, phenyl, tolyl or C1-4alkyl.

### Claim 2 (depends on 1)

The compound of formula (I) of claim 1, or a pharmaceutically acceptable salt thereof
wherein:
ring A is pyridinyl or phenyl;
ring B is pyridinyl or phenyl;
R1 and R2 combine to form a C3-6 cycloalkyl wherein said C3-6 cycloalkyl is optionally substituted with 1, 2 or 3 halogens;
R3 is —O—C0-3alkyl-C3-8 cycloalkyl-C0-4alkyl, —O—C9-10bicycloalkyl-C0-4alkyl, —NH—C3-8 cycloalkyl-C0-4alkyl, phenyl, pyridyl, C9-10 heteroaryl, C3-8 cycloalkyl, C4-7 heterocycloalkyl, C6-12 spirocycloalkyl, spirocyclic heterocycle, a 7 to 10 membered fused heterocycle, C5-6 heterocycloalkene or C3-6 cycloalkene, wherein said phenyl, pyridyl, C9-10 heteroaryl, C3-8 cycloalkyl, C4-7 heterocycloalkyl, C6-12 spirocycloalkyl, spirocyclic heterocycle, C5-6 heterocycloalkene or C3-6 cycloalkene is optionally substituted with 1 to 4 substituents each independently selected from halogen, CD3, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, pyridinyl and halo-substituted-C1-4alkoxy, or R3 is C1-4alkyl, CD3, C1-5alkoxy or C1-4alkenyl, wherein said C1-4alkyl, C1-4alkenyl or C1-4alkoxy is optionally substituted with 1 to 3 substituents each independently selected from halogen and an optionally substituted phenyl wherein said phenyl is substituted with halo-substituted-C1-2alkyl, methyl or 1, 2 or 3 halogens;
R4 is C1-4alkyl, C1-4alkoxy, CD3, halogen or halo-substituted-C1-4alkyl;
R5 is —NR7R8 or R9;
R6 is hydrogen or halogen;
R7 is hydrogen, C1-6alkyl, C3-6 cycloalkyl, C4-7 heterocycloalkyl, wherein said C1-6alkyl, C3-6 cycloalkyl or C4-7 heterocycloalkyl is optionally substituted with 1 to 4 substituents each independently selected from deuterium, hydroxy, C1-4alkoxy, C1-4alkyl and C3-6 cycloalkyl;
R8 is hydrogen or C1-4alkyl;
R9 is a saturated C4-7 heterocycloalkyl optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, optionally substituted phenyl, optionally substituted pyridinyl, NHR11, —C(O)—R13, —C(O)NHR12, C1-4alkyl-C(O)OR12 and —C(O)O—R12, wherein said optionally substituted phenyl or pyridinyl, is substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino and C1-4alkyl, or R9 is perdeuterated morpholinyl, a 7 to 10 membered fused heterocycle or spirocyclic heterocycle optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, C3-6 cycloalkyl, phenyl, C4-6 heterocycle, NHR11, —S(O)2—R15, —C(O)—R13, —C(O)NHR11, C1-4alkyl-C(O)OR12, —C(O)C1-3alkyl-NHR11 and —C(O)O—R12, wherein said phenyl, C3-6 cycloalkyl and C4-6 heterocycle are optionally substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino, C1-4alkyl, halo-substituted-C1-4alkyl and hydroxy-substituted-C1-4alkyl;
R11 is hydrogen, C1-4alkyl, —C(S)NH—R15, —C(O)NH—R15, —C(O)R15 or C0-3alkyl-C(O)O—R14;
R12 is hydrogen, C1-4alkyl, C3-6 cycloalkyl or C1-3alkyl-C(O)—NHR14;
R13 is C1-4alkyl, wherein said alkyl is optionally substituted with amino;
R14 is hydrogen or C1-4alkyl; and
R15 is C3-6 cycloalkyl, phenyl, tolyl or C1-4alkyl.

### Claim 3 (depends on 1)

The compound of claim 1 having the structure of formula (Ia), or a pharmaceutically acceptable salt thereof:
wherein:
Y1 is N or CH; and
Y2 is CH or N.

### Claim 4 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof wherein:
Y1 is N;
Y2 is CH;
R3 is phenyl, pyridyl or C9-10 heteroaryl, wherein said phenyl, pyridyl or C9-10 heteroaryl, is optionally substituted with 1 to 4 substituents each independently selected from halogen, CD3, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy.

### Claim 5 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof wherein:
Y1 is N;
Y2 is CH;
R3 is C3-8 cycloalkyl, C4-7 heterocycloalkyl, —O—C0-3alkyl-C3-8 cycloalkyl, C6-12 spirocycloalkyl, C5-6 heterocycloalkene or C3-6 cycloalkene, wherein said C3-8 cycloalkyl, C4-7 heterocycloalkyl, C6-12 spirocycloalkyl, C5-6 heterocycloalkene or C3-6 cycloalkene, is optionally substituted with 1 to 4 substituents each independently selected from halogen, C1-4alkyl, hydroxy, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy.

### Claim 6 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof wherein:
Y1 is N;
Y2 is CH;
R3 is C1-4alkyl, CD3, C1-4alkoxy or C1-4alkenyl, wherein said C1-4alkyl, C1-4alkenyl or C1-4alkoxy is optionally substituted with 1 to 3 substituents each independently selected from halogen and an optionally substituted phenyl wherein said phenyl is substituted with halo-substituted-C1-2alkyl, methyl or 1, 2 or 3 halogens.

### Claim 7 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof wherein:
Y1 is N;
Y2 is N;
R3 is phenyl, pyridyl or C9-10 heteroaryl, wherein said phenyl, pyridyl or C9-10 heteroaryl, is optionally substituted with 1 to 4 substituents each independently selected from halogen, CD3, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy.

### Claim 8 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof wherein:
Y1 is N;
Y2 is N;
R3 is C3-8 cycloalkyl, C4-7 heterocycloalkyl, —O—C0-3alkyl-C3-8 cycloalkyl, C6-12 spirocycloalkyl, C5-6 heterocycloalkene or C3-6 cycloalkene, wherein said C3-8 cycloalkyl, C4-7 heterocycloalkyl, C6-12 spirocycloalkyl, C5-6 heterocycloalkene or C3-6 cycloalkene, is optionally substituted with 1 to 4 substituents each independently selected from halogen, C1-4alkyl, hydroxy, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy.

### Claim 9 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof wherein:
Y1 is N;
Y2 is N;
R3 is C1-4alkyl, CD3, C1-4alkoxy or C1-4alkenyl, wherein said C1-4alkyl, C1-4alkenyl or C1-4alkoxy is optionally substituted with 1 to 3 substituents each independently selected from halogen and an optionally substituted phenyl wherein said phenyl is substituted with halo-substituted-C1-2alkyl, methyl or 1, 2 or 3 halogens.

### Claim 10 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:
R6 is hydrogen.

### Claim 11 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:
R6 is fluoro or chloro.

### Claim 12 (depends on 3)

The compound of claim 3 having the structure of formula (Ib) or a pharmaceutically acceptable salt thereof:
wherein:
R3 is selected from the group consisting of:
X is CH or N;
R4 is CH3, CD3, —OCH3, Cl, F or CF3;
R5 is R9;
R9 is a saturated C4-7 heterocycloalkyl optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, optionally substituted phenyl, NHR11, —C(O)NHR12, C1-4alkyl-C(O)OR12 and —C(O)O—R12, wherein said optionally substituted phenyl, is substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino and C1-4alkyl;
R11 is hydrogen, C1-4alkyl, —C(O)NH—R15, —C(O)R15 or C0-3alkyl-C(O)O—R14;
R12 is hydrogen, C1-4alkyl, C3-6 cycloalkyl or C1-3alkyl-C(O)—NHR14;
R14 is hydrogen or C1-4alkyl;
R15 is C3-6 cycloalkyl, tolyl or C1-4alkyl;
R16 is selected from hydrogen, CD3, halogen, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy;
R17 is selected from hydrogen, CD3, halogen, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy; and
R18 is selected from hydrogen and halogen.

### Claim 13 (depends on 3)

The compound of claim 3 having the structure of formula (Ib), or a pharmaceutically acceptable salt thereof:
wherein:
R3 is selected from the group consisting of:
Z is CH2 or O;
R4 is CH3, CD3, —OCH3, Cl, F or CF3;
R5 is R9;
R9 is a saturated C4-7 heterocycloalkyl optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, optionally substituted phenyl, NHR11, —C(O)NHR12, C1-4alkyl-C(O)OR12 and —C(O)O—R12, wherein said optionally substituted phenyl, is substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino and C1-4alkyl;
R11 is hydrogen, C1-4alkyl, —C(O)NH—R15, —C(O)R15 or C0-3alkyl-C(O)O—R14;
R12 is hydrogen, C1-4alkyl, C3-6 cycloalkyl or C1-3alkyl-C(O)—NHR14;
R14 is hydrogen or C1-4alkyl;
R15 is C3-6 cycloalkyl, tolyl or C1-4alkyl;
R19 is selected from hydrogen, C1-4alkyl, halo-substituted-C1-4alkyl and halogen;
R20 is selected from hydrogen, C1-4alkyl and halogen; or R19 and R20 may combine to form an optionally substituted C3-6 cycloalkyl or C4-6 heterocycloalkyl ring; and
R21 is selected from hydrogen, C1-4alkyl, halo-substituted-C1-4alkyl and halogen.

### Claim 14 (depends on 3)

The compound of claim 3 having the structure of formula (Ic), or a pharmaceutically acceptable salt thereof:
wherein:
R4 is CH3, CD3, —OCH3, Cl, F or CF3;
R5 is R9;
R9 is a saturated C4-7 heterocycloalkyl optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, optionally substituted phenyl, NHR11, —C(O)NHR12, C1-4alkyl-C(O)OR12 and —C(O)O—R12, wherein said optionally substituted phenyl, is substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino and C1-4alkyl;
R11 is hydrogen, C1-4alkyl, —C(O)NH—R15, —C(O)R15 or C0-3alkyl-C(O)O—R14;
R12 is hydrogen, C1-4alkyl, C3-6 cycloalkyl or C1-3alkyl-C(O)—NHR14;
R14 is hydrogen or C1-4alkyl;
R15 is C3-6 cycloalkyl, tolyl or C1-4alkyl;
R16 is selected from hydrogen, CD3, halogen, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy; and
R17 is selected from hydrogen, CD3, halogen, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl and halo-substituted-C1-4alkoxy.

### Claim 15 (depends on 13)

The compound of claim 13 having the structure of formula (Id), or a pharmaceutically acceptable salt thereof:
wherein:
Z is CH2 or O;
R4 is CH3, CD3, —OCH3, Cl, F or CF3;
R5 is R9;
R9 is a saturated C4-7 heterocycloalkyl optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, optionally substituted phenyl, NHR11, —C(O)NHR12, C1-4alkyl-C(O)OR12 and —C(O)O—R12, wherein said optionally substituted phenyl, is substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino and C1-4alkyl;
R11 is hydrogen, C1-4alkyl, —C(O)NH—R15, —C(O)R15 or C0-3alkyl-C(O)O—R14;
R12 is hydrogen, C1-4alkyl, C3-6 cycloalkyl or C1-3alkyl-C(O)—NHR14;
R14 is hydrogen or C1-4alkyl;
R15 is C3-6 cycloalkyl, tolyl or C1-4alkyl;
R19 is selected from hydrogen, C1-4alkyl, halo-substituted-C1-4alkyl and halogen;
R20 is selected from hydrogen, C1-4alkyl and halogen; or R19 and R20 may combine to form an optionally substituted C3-6 cycloalkyl or C4-6 heterocycloalkyl ring; and
R21 is selected from hydrogen, C1-4alkyl, halo-substituted-C1-4alkyl and halogen.

### Claim 16 (depends on 13)

The compound of claim 13 having the structure of formula (Ie), or a pharmaceutically acceptable salt thereof:
wherein:
R4 is CH3, CD3, —OCH3, Cl, F or CF3;
R5 is R9;
R9 is a saturated C4-7 heterocycloalkyl optionally substituted with 1 to 4 substituents each independently selected from deuterium, halogen, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl, hydroxy-substituted-C1-4alkyl, oxo, nitrile, optionally substituted phenyl, NHR11, —C(O)NHR12, C1-4alkyl-C(O)OR12 and —C(O)O—R12, wherein said optionally substituted phenyl, is substituted with 1 to 3 substituents each independently selected from hydroxy, halogen, amino and C1-4alkyl;
R11 is hydrogen, C1-4alkyl, —C(O)NH—R15, —C(O)R15 or C0-3alkyl-C(O)O—R14;
R12 is hydrogen, C1-4alkyl, C3-6 cycloalkyl or C1-3alkyl-C(O)—NHR14;
R14 is hydrogen or C1-4alkyl;
R15 is C3-6 cycloalkyl, tolyl or C1-4alkyl;
R19 is selected from hydrogen, C1-4alkyl, halo-substituted-C1-4alkyl and halogen;
R20 is selected from hydrogen, C1-4alkyl and halogen; or R19 and R20 may combine to form an optionally substituted C3-6 cycloalkyl or C4-6 heterocycloalkyl ring; and
R21 is selected from hydrogen, C1-4alkyl, halo-substituted-C1-4alkyl and halogen.

### Claim 17 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein:
R4 is CD3, CH3, Cl, CF3 or F.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 14)

The compound of claim 14, or a pharmaceutically acceptable salt thereof, wherein:
R5 is R9; and
R9 is selected from the group consisting of:
R22 is hydrogen, deuterium, chloro, fluoro, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl or hydroxy-substituted-C1-4alkyl; and
R23 is hydrogen, chloro, fluoro, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl or hydroxy-substituted-C1-4alkyl; or R22 and R23 may combine to form oxo.

### Claim 22 (depends on 1)

The compound of claim 1, selected from the group consisting of:
N-((6-Aminopyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropane-1-carboxamide;
N-((6-Aminopyridin-2-yl)sulfonyl)-1-((3′-fluoro-5′-isobutoxy-4-methyl-[1,1′-biphenyl]-2-yl)oxy)cyclopropane-1-carboxamide;
N-((6-aminopyridin-2-yl)sulfonyl)-1-(5-methyl-2-(2-(trifluoromethyl)cyclopropyl)phenoxy)cyclopropane-1-carboxamide;
N-((6-Aminopyridin-2-yl)sulfonyl)-1-(2-(4,4-difluorocyclohexyl)-5-methylphenoxy)cyclopropane-1-carboxamide;
N-((6-Aminopyridin-2-yl)sulfonyl)-1-(2-(3,3-difluorocyclohexyl)-5-methylphenoxy)cyclopropane-1-carboxamide;
N-((6-Aminopyridin-2-yl)sulfonyl)-1-(2-cycloheptyl-5-methylphenoxy)cyclopropane-1-carboxamide;
N-((6-Amino-3-fluoropyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropane-1-carboxamide;
N-((6-Aminopyridin-2-yl)sulfonyl)-1-(5-methyl-2-(1-(trifluoromethyl)cyclopropyl)phenoxy)cyclopentane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(3-hydroxyazetidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
(S)-1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(3-methylmorpholino)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
Methyl 1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-4-methylpiperidine-4-carboxylate;
Methyl 1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropane-1-carbonyl)sulfamoyl)pyridin-2-yl)piperidine-4-carboxylate;
1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-4-methylpiperidine-4-carboxylic acid;
1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)piperidine-4-carboxylic acid;
Cyclopentyl 1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)piperidine-4-carboxylate;
Tert-butyl (1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-4-methylpiperidin-4-yl)carbamate;
N-((6-(4-Amino-4-methylpiperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(4-(cyclopropanecarboxamido)-4-methylpiperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(4-(3-cyclopropylureido)-4-methylpiperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
Tert-butyl (1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)piperidin-3-yl)carbamate;
N-((6-(3-Aminopiperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-4-methylpiperidine-4-carboxamide;
N-((6-(4-Cyano-4-methylpiperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
N-((6-(4-Amino-4-(trifluoromethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(3-methoxyazetidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
N-((6-(4-Amino-4-(fluoromethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
N-((6-(1-Amino-8-azaspiro[4.5]decan-8-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
N-((6-(1,6-Diazaspiro[3.3]heptan-6-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
Tert-butyl (1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-4-(hydroxymethyl)piperidin-4-yl)carbamate;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(4-(3-cyclopropylthioureido)-4-methylpiperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
Tert-butyl (1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-3-methylpyrrolidin-3-yl)carbamate;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(dimethylamino)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
(R)-1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(3-methylmorpholino)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
N-((6-(3-Amino-3-methylpyrrolidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(6-fluoro-4-oxospiro[chroman-2,4′-piperidin]-1′-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
Tert-butyl 6-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-2,6-diazaspiro[3.3]heptane-2-carboxylate;
Tert-butyl 6-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-1,6-diazaspiro[3.3]heptane-1-carboxylate;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(piperazin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
N-((6-(1-Amino-8-azaspiro[4.5]decan-8-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
N-((6-(1-Amino-8-azaspiro[4.5]decan-8-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(3-oxopiperazin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
Tert-butyl 4-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)piperazine-1-carboxylate;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-((trans-3-hydroxycyclobutyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-((cis-3-hydroxycyclobutyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(3-(trifluoromethyl)piperazin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
Methyl 3-(4-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)piperazin-1-yl)-2,2-dimethylpropanoate;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(morpholino-d8)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(5-oxo-1,4-diazepan-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
N-((6-(4-Aminopiperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarboxamide;
Tert-butyl (1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)-4-(fluoromethyl)piperidin-4-yl)carbamate;
Tert-butyl (1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropanecarbonyl)sulfamoyl)pyridin-2-yl)piperidin-4-yl)carbamate;
N-((6-(5-cis-amino-3-azabicyclo[4.1.0]heptan-3-yl)pyridin-2-yl)sulfonyl)-1-(2-cyclohexyl-5-methylphenoxy)cyclopropane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(R)-1-(2-cyclohexyl-5-methylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-((2-hydroxypropyl)(methyl)amino)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(4-hydroxy-4-methylpiperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
Tert-butyl (1-(6-(N-(1-(2-cyclohexyl-5-methylphenoxy)cyclopropane-1-carbonyl)sulfamoyl)pyridin-2-yl)-3-methylazetidin-3-yl)carbamate;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(2-methylmorpholino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(2-methylmorpholino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(R)-1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(2-methylmorpholino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(4-phenylpiperazin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(4-(4-fluorophenyl)piperazin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-Cyclohexyl-5-methylphenoxy)-N-((6-(6-tosyl-1,6-diazaspiro[3.3]heptan-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(5-Chloro-2-cyclohexylphenoxy)-N-((6-(3-hydroxyazetidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-(4,4-Difluorocyclohexyl)-5-methylphenoxy)-N-((6-(6′-fluoro-4′-oxo-3′,4′-dihydro-1′H-spiro[piperidine-4,2′-quinolin]-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
(S)-1-(2-(4,4-Difluorocyclohexyl)-5-fluorophenoxy)-N-((6-((1-hydroxypropan-2-yl)amino)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
(S)-1-(2-(4,4-Difluorocyclohexyl)-5-methylphenoxy)-N-((6-(3-(hydroxymethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(R)-1-(2-(4,4-Difluorocyclohexyl)-5-methylphenoxy)-N-((6-(3-(hydroxymethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(R)-1-(2-(4,4-Difluorocyclohexyl)-5-methylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(R)-1-(2-(4,4-Difluorocyclohexyl)-5-methylphenoxy)-N-((6-((1-hydroxypropan-2-yl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
Tert-butyl (1-(6-(N-(1-(2-(4,4-difluorocyclohexyl)-5-methylphenoxy)cyclopropane-1-carbonyl)sulfamoyl)pyridin-2-yl)-3-methylazetidin-3-yl)carbamate;
(S)-1-(2-(4,4-Difluorocyclohexyl)-5-methoxyphenoxy)-N-((6-(3-(hydroxymethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-(Trans-4-fluorocyclohexyl)-5-methylphenoxy)-N-((6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-(2,5-Dimethylphenoxy)-N-((6-(3-methylmorpholino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-(3,3-Difluorocyclobutyl)-5-methylphenoxy)-N-((6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
(R)-1-(2,5-dimethylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopentane-1-carboxamide;
(S)-1-(2-Cyclopentyl-5-methylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(R)-1-(2-Cyclopentyl-5-methylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-(3,3-Difluorocyclopentyl)-5-methylphenoxy)-N-((6-((R)-3-(hydroxymethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(R)—N-((6-(3-(hydroxymethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-isobutyl-5-methylphenoxy)cyclopropane-1-carboxamide;
(S)—N-((6-((2-Hydroxypropyl)amino)pyridin-2-yl)sulfonyl)-1-(2-isobutyl-5-methylphenoxy)cyclopropane-1-carboxamide;
(R)—N-((6-((2-Hydroxypropyl)amino)pyridin-2-yl)sulfonyl)-1-(2-isobutyl-5-methylphenoxy)cyclopropane-1-carboxamide;
(S)-1-(5-Chloro-2-isobutylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(5-Chloro-2-(spiro[2.5]octan-6-yl)phenoxy)-N-((6-(3-hydroxyazetidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(R)-1-(5-Chloro-2-(4,4-dimethylcyclohexyl)phenoxy)-N-((6-(2-methylmorpholino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-(2-Cyclopropyl-5-methylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-(5-Chloro-2-cyclopropylphenoxy)-N-((6-((2-hydroxypropyl)amino)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)—N-((6-((2-Hydroxypropyl)amino)pyridin-2-yl)sulfonyl)-1-(5-methyl-2-(1-methylcyclopropyl)phenoxy)cyclopropane-1-carboxamide;
N-((6-(3-Hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)sulfonyl)-1-(5-methyl-2-(1-(trifluoromethyl)cyclopropyl)phenoxy)cyclopropane-1-carboxamide;
1-(5-Fluoro-2-(3,3,3-trifluoroprop-1-en-2-yl)phenoxy)-N-((6-(4-phenylpiperazin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)—N-((6-(3-Hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)-1-(5-methyl-2-(spiro[3.3]heptan-2-yl)phenoxy)cyclopropane-1-carboxamide;
N-((6-((R)-3-(hydroxymethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(5-methyl-2-(tetrahydro-2H-pyran-3-yl)phenoxy)cyclopropane-1-carboxamide;
(R)-1-(2-(3,4-Dihydro-2H-pyran-5-yl)-5-methylphenoxy)-N-((6-(3-(hydroxymethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
N-((6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)sulfonyl)-1-((4-methyl-1′,2′,3′,6′-tetrahydro-[1,1′-biphenyl]-2-yl)oxy)cyclopropanecarboxamide;
1-(2-(cis-4-fluorocyclohexyl)-5-methylphenoxy)-N-((6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-(6,6-Dimethyltetrahydro-2H-pyran-3-yl)-5-methylphenoxy)-N-((6-((S)-3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-((S)-6,6-dimethyltetrahydro-2H-pyran-3-yl)-5-methylphenoxy)-N-((6-((S)-3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-(2-((R)-6,6-dimethyltetrahydro-2H-pyran-3-yl)-5-methylphenoxy)-N-((6-((S)-3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)—N-((6-(3-Hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)-1-((4-methyl-3′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)oxy)cyclopropane-1-carboxamide;
(S)-1-((4-Chloro-3′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)oxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
1-((4-Chloro-3′-isobutoxy-[1,1′-biphenyl]-2-yl)oxy)-N-((6-(4-cyano-4-methylpiperidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-(2-(Benzofuran-6-yl)-5-chlorophenoxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-((3′,4-Bis(trifluoromethyl)-[1,1′-biphenyl]-2-yl)oxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-((4-Chloro-3′-(trifluoromethoxy)-[1,1′-biphenyl]-2-yl)oxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)-1-((4-Chloro-4′-fluoro-3′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)oxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
N-((6-(3-Hydroxy-3-methylazetidin-1-yl)pyridin-2-yl)sulfonyl)-1-((4-methyl-3′-(trifluoromethoxy)-[1,1′-biphenyl]-2-yl)oxy)cyclopropane-1-carboxamide;
(S)-1-((3′-(Difluoromethyl)-4-methyl-[1,1′-biphenyl]-2-yl)oxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)—N-((6-(3-Hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)-1-((4-methyl-4′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)oxy)cyclopropane-1-carboxamide;
(R)—N-((6-(3-Hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)-1-((4-methyl-3′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)oxy)cyclopropane-1-carboxamide;
(S)-1-(2-(Benzofuran-5-yl)-5-chlorophenoxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
(S)—N-((6-(3-Hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)-1-(5-methyl-2-(4-(trifluoromethyl)pyridin-2-yl)phenoxy)cyclopropane-1-carboxamide;
(S)—N-((6-(3-Hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)-1-((4-methyl-2′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)oxy)cyclopropane-1-carboxamide;
(S)-1-(5-Chloro-2-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)phenoxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
N-((6-(4-Amino-4-(trifluoromethyl)piperidin-1-yl)pyridin-2-yl)sulfonyl)-1-((4-methyl-3′-(trifluoromethyl)-[1,1′-biphenyl]-2-yl)oxy)cyclopropane-1-carboxamide;
(S)-1-(2-(Benzyloxy)-5-methylphenoxy)-N-((6-(2-methylmorpholino)pyridin-2-yl)sulfonyl)cyclopropanecarboxamide;
N-((6-(4-Cyano-4-methylpiperidin-1-yl)pyridin-2-yl)sulfonyl)-1-(2-(cyclopentyloxy)-5-methylphenoxy)cyclopropanecarboxamide; and
(S)-1-(2-(Cyclohexyloxy)-5-methylphenoxy)-N-((6-(3-hydroxypyrrolidin-1-yl)pyridin-2-yl)sulfonyl)cyclopropane-1-carboxamide;
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, or diluent.

### Claim 24 (depends on 23)

The pharmaceutical composition of claim 23, further comprising one or more additional pharmaceutical agent(s).

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the additional pharmaceutical agent(s) is selected from a mucolytic agent, nebulized hypertonic saline, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator and an anti-inflammatory agent.

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 24)

The pharmaceutical composition of claim 24, wherein the additional pharmaceutical agents are a CFTR modulator and a CFTR potentiator.

### Claim 30 (depends on 1)

A method for treating a CFTR mediated disease in a subject comprising administering to the subject a compound or a pharmaceutically acceptable salt thereof of claim 1.

### Claim 31 (depends on 30)

The method of claim 30, wherein the CFTR mediated disease is selected from cystic fibrosis, asthma, COPD, emphysema and chronic bronchitis.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 1, 30)

The method of claim 30, further comprising administering to the subject one or more additional pharmaceutical agent(s) prior to, concurrent with, or subsequent to the compound of claim 1.

### Claim 35 (depends on 34)

The method of claim 34, wherein the additional pharmaceutical agent(s) is selected from a mucolytic agent, nebulized hypertonic saline, bronchodilator, an antibiotic, an anti-infective agent, a CFTR modulator and an anti-inflammatory agent.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 34)

The method of claim 34, wherein the additional pharmaceutical agents are a CFTR modulator and a CFTR potentiator.

### Claim 39 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein:
R4 is CD3, CH3, Cl, CF3 or F.

### Claim 40 (depends on 15)

The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein:
R5 is R9; and
R9 is selected from the group consisting of:
R22 is hydrogen, deuterium, chloro, fluoro, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl or hydroxy-substituted-C1-4alkyl; and
R23 is hydrogen, chloro, fluoro, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl or hydroxy-substituted-C1-4alkyl; or R22 and R23 may combine to form oxo.

### Claim 41 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein:
R4 is CD3, CH3, Cl, CF3 or F.

### Claim 42 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein:
R5 is R9; and
R9 is selected from the group consisting of:
R22 is hydrogen, deuterium, chloro, fluoro, hydroxy, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl or hydroxy-substituted-C1-4alkyl; and
R23 is hydrogen, chloro, fluoro, C1-4alkyl, C1-4alkoxy, halo-substituted-C1-4alkyl or hydroxy-substituted-C1-4alkyl; or R22 and R23 may combine to form oxo.
